In vivo antitumor activity of a novel orally bioavailable ifosfamide nanostructured lipid carrier against Dalton's ascitic lymphoma

Journal of Pharmaceutical Innovation

Volumn 9, Issue 3, 2014, Pages 203-211

  Velmurugan, Ramaiyan ^a   Selvamuthukumar, Subramanian ^a  

^a ANNAMALAI UNIVERSITY   (India)

Author keywords

Bioavailability; Dalton's ascitic lymphoma; Ifosfamide; In vivo antitumor activity; Nanostructured lipid carrier; Oral delivery

Indexed keywords

ALGINIC ACID; CHOLESTEROL; HEMOGLOBIN; IFOSFAMIDE; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASCITES TUMOR; CELL COUNT; CONTROLLED STUDY; CROSS LINKING; DALTON ASCITICL YMPHOMA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; ERYTHROCYTE COUNT; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; LEUKOCYTE COUNT; LYMPHOMA; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; SURVIVAL TIME; TRIACYLGLYCEROL BLOOD LEVEL; TUMOR VOLUME;

EID: 84908355867     PISSN: 18725120     EISSN: 19398042     Source Type: Journal    
DOI: 10.1007/s12247-014-9187-0     Document Type: Article

References (26)

1. KunduSen S, Gupta M, Mazumder UK, Haldar PK, Saha P, Bala A. Antitumor activity of Citrusmaxima (Burm.) Merr.leaves in Ehrlich's ascites carcinoma cell-treated mice, ISRN Pharmacology, 2011.
2. Chatterjee D, Sahu RK, Jha AK, Dwivedi J. Evaluation of antitumor activity of Cuscuta reflexa Roxb (Cuscutaceae) against Ehrlich ascites carcinoma in Swiss albino mice. Trop J Pharm Res. 2011;10:443-7.
3. Osawa T, Kawakishi S, Namiki M. Antitumutagenesis and anticarcinogenesis mechanism II. New York: Plenum; 1990.
4. Aleksa K, Nava Ocampo A, Koren G. Detection and quantification of (R) and (S)-dechloroethylifosfamide metabolites in plasma from children by enantioselective LC/MS/MS. Chirality. 2009;21:674-80.
5. Pandit AA, Dash AK. Surface modified lipid nanoparticulate formulation for ifosfamide: development and characterization. Nanomedicine. 2011;8:1397-412.
6. Yuan H, Wang LL, Du YZ, You Hu FQ, Zeng S. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloids Surf B: Biointerfaces. 2007;2:174-9. (Pubitemid 350030429)
7. Hu FQ, Zhang Y, Du YZ, Yuan H. Nimodipine loaded lipid nanospheres prepared by solvent diffusion method in a drug saturated aqueous system. Int J Pharm. 2008;2:146-52. (Pubitemid 350266243)
8. Agarwal RC, Rachana J, Wasim R, Ovais M. Anti-carcinogenic effects of Solanum lycopersicum fruit extract on Swiss albino and C57B1 mice. Asian Pac J Cancer Prev. 2009;10:379-82.
9. Becerra DP, Castro FO, Alves APNN, Dessoa C, Moraes MO, Silveria ER, et al. In vivo growth-inhibition of sarcoma 180 by piplartine and piperine two alkaloid amides from piper. Braz J Med Biol Res. 2006;39:801-7. (Pubitemid 43880939)
10. Appleman D, Skavinski ER, Stein AM. Catalase studies on normal and cancerous rats. Cancer Res. 1950;10:498-505.
11. Chitra V, Shrinivas S, Nandu K. Evaluation of anticancer activity of Vitex negundo study. Int J Pharmacol Technol Res. 2009;4:1485-9.
12. Haldar PK, Kar B, Bala A, Bhattacharya S, Mazumder UK. Antitumor activity of Sansevieria roxburghiana rhizomeagainst Ehrlich ascites carcinoma in mice. Pharm Biol. 2010;48:1330-7.
13. Bala A, Kar B, Haldar PK, Majumder UK, Bera S. Evaluation of anticancer activity of Cleome gynandra on Ehrlich's ascites carcinoma treated mice. J Ethnopharmacol. 2010;19:129-31.
14. Ratzinger G, Fillafer C, Kerleta V, Wirth M, Gabor F. The role of surface functionalization in the design of PLGA micro- and nanoparticles. Crit Rev Ther Drug Carrier Syst. 2010;27:1-83.
15. Delie F. Evaluation of nano and microparticle uptake by the gastrointestinal tract. Adv Drug Deliv Rev. 1988;34:221-33.
16. McClean S, Prosser E, Meehan E. Binding and uptake of biodegradable poly-DL-lactide micro and nanoparticles in intestinal epithelia. Eur J Pharm Sci. 1998;6:153-63. (Pubitemid 28164286)
17. Dong Y, Feng SS. Poly (D, L-lactide-co-glycolide) montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26:6068-76. (Pubitemid 40805612)
18. O'Hagan DT, Jeffery H, Roberts MJ, McGee JP, Davis SS. Controlled release microparticles for vaccine development. Vaccine. 1991;9:768-71.
19. Hancock BC, Carlson GT, Ladipo DD, Langdon BA, Mullarney MP. Comparison of the mechanical properties of the crystalline and amorphous forms of a drug substance. Int J Pharm. 2002;241:73-85. (Pubitemid 34667068)
20. Corrigan DO, Healy AM, Corrigan OI. The effect of spray drying solutions of bendroflumethiazide/polyethylene glycol on the physicochemical properties of the resultant materials. Int J Pharm. 2003;262:125-37. (Pubitemid 36966700)
21. Schmoll HJ, Rhomberg W, Diehl V. Activity in testicular cancer using mono and combination chemotherapy. Int Curr Chemother. 1978;2:1089-91.
22. Schmoll HJ. The role of ifosfamide in testicular cancer. Semin Oncol. 1989;16:82-93.
23. Loehrer PJ, Einhorn LH, Williams SD. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol. 1986;4:528-36. (Pubitemid 16117943)
24. Bokemeyer C, Schmoll HJ. The antitumor activity of ifosfamide on heterotrasplanted testicular cancer cell lines remains unaltered by uroprotector mesna. Br J Cancer. 1994;69:863-7. (Pubitemid 24140665)
25. Prasad B, Giri A. Antitumor effect of cisplatin againstmurine ascites Dalton's lymphoma. Indian J Exp Biol. 1994;32:155.
26. Karmakar I, Dolai N, Saha P, Sarkar N, Bala A, Haldar PK. Scavenging activity of Curcuma caesia against reactive oxygen and nitrogen species. Orient Pharm Exp Med. 2011;11:221.